# A randomized, double-blind, placebo-controlled, phase 2 study of RMP-7 in combination with carboplatin administered intravenously for the treatment of recurrent malignant glioma

Source: https://onco.cc/key-papers/paper-carboplatin-glioblastoma-neuro-oncol-2003/  
OnCo record `paper-carboplatin-glioblastoma-neuro-oncol-2003` (Key paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Phase 2 or 3 results paper on Carboplatin in Glioma & glioblastoma, in Neuro-Oncology (2003), one of the most cited Europe PMC records with Carboplatin in its title.

## Summary

RMP-7, a bradykinin analog, temporarily increases the permeability of the blood-brain tumor barrier to chemotherapy drugs like carboplatin. We conducted a randomized, controlled trial of carboplatin and RMP-7 versus carboplatin and placebo in patients with recurrent malignant glioma. The primary outcome measure was time to tumor progression (TTP). Adults with recurrent glioblastoma multiforme or anaplastic glioma were randomized in a 1:1 ratio to receive carboplatin and either RMP-7 or placebo. Radiation therapy had failed in all patients, and they may have received prior chemotherapy. Carboplatin (dosed to achieve an area under the curve of 5 mg/ml x time for patients who had received prior chemotherapy, or 7 mg/ml x time for those who had not) was given intravenously every 4 weeks, followed by intravenous infusion of either RMP-7 or placebo (300 ng/kg). TTP, tumor response, neuropsychological assessments, functional independence, and quality of life assessments were analyzed every 4 weeks. There were 122 patients enrolled, 62 in the RMP-7 and carboplatin group and 60 in the placebo and carboplatin group. Median TTP was 9.7 weeks (95% CI, 8.3-12.6 weeks) for the RMP-7 and carboplatin group and 8.0 weeks (95% CI, 7.4-12.6 weeks) for the placebo and carboplatin group. Median survival times were 26.9 weeks (95% CI, 21.3-37.6 weeks) for the RMP-7 group and 19.9 weeks (95% CI, 15.0-31.3 weeks) for the placebo group. No differences were noted for time to worsening of neuropsychological assessments, functional independence, or quality of life assessments. The use of RMP-7 had no effect on the pharmacokinetics or toxicity of carboplatin. At the dose and schedule used in this trial, RMP-7 did not improve the efficacy of carboplatin. Recent preclinical pharmacokinetic modeling of RMP-7 suggests that higher doses of RMP-7 may be required to increase carboplatin delivery to tumor.

Indexed on Europe PMC as PubMed record 12672281 (DOI 10.1093/neuonc/5.2.96). Its title names Carboplatin and its text names Glioma & glioblastoma; PubMed types it as a clinical trial report (Clinical Trial, Phase II, Comparative Study, Clinical Trial, Research Support, U.S. Gov't, P.H.S., Research Support, Non-U.S. Gov't, research-article, Multicenter Study, Randomized Controlled Trial). It was matched automatically to the idea "A skull ultrasound implant that opens the barrier at every cycle" and no figure has been checked by an editor.

## Fields

- Kind: Key paper
- Last checked: 2026-09-22
- Tags: europepmc-ingest
- Journal: Neuro-Oncology
- Year: 2003
- DOI: 10.1093/neuonc/5.2.96
- Authors: Prados MD, Schold SC, Fine HA, et al.
- What it means: One of the most cited trial reports Europe PMC returns for Carboplatin in Glioma & glioblastoma, so it is a natural first reading for anyone weighing the idea it is linked from. The record was linked automatically by title and abstract; read the abstract above and the paper itself before relying on any figure.
- Caveats: Matched by Carboplatin in the title and Glioma & glioblastoma in the title or abstract of the Europe PMC record; the summary reproduces the record's abstract and no figure has been verified against the full paper.; Chosen as a phase 2 or 3 report by the record's publication type or its own wording, not by reading the paper.

## Sources

- Neuro Oncol 2003: https://doi.org/10.1093/neuonc/5.2.96
- PubMed: https://pubmed.ncbi.nlm.nih.gov/12672281/
- Europe PMC: https://europepmc.org/article/MED/12672281

## Connected records

- journals: [Neuro-Oncology](https://onco.cc/journals/neuro-oncology/)
- ideas: [A skull ultrasound implant that opens the barrier at every cycle](https://onco.cc/ideas/idea-bio2-implanted-ultrasound-repeat-dosing/)

---
JSON: https://onco.cc/api/v1/entities/paper-carboplatin-glioblastoma-neuro-oncol-2003.json